The impact of regulations, safety considerations and physical limitations on research progress at maximum biocontainment

Viruses

Volumn 4, Issue 12, 2012, Pages 3932-3951

  Shurtleff, Amy C ^a   Garza, Nicole ^a   Lackemeyer, Matthew ^b   Carrion, Ricardo ^c   Griffiths, Anthony ^c   Patterson, Jean ^c   Edwin, Samuel S ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Biocontainment; Biodefense; Biological select agents and toxins (BSAT); Biosafety level 4 (BSL 4); Biosecurity; Collaboration; Ebola virus; Highly pathogenic viruses; Limitations; Positive pressure suit

Indexed keywords

TOXIN;

ACCURACY; AUTOPSY; BIOSAFETY; BIOTECHNOLOGY; CLINICAL LABORATORY; CLINICAL RESEARCH; EBOLA VIRUS; EXPERIMENT; EXPERIMENTAL ANIMAL; FOOD AND DRUG ADMINISTRATION; GOOD LABORATORY PRACTICE; HEALTH HAZARD; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERPERSONAL COMMUNICATION; LABORATORY DEVICE; LABORATORY PERSONNEL; MICROORGANISM; MONITORING; NONHUMAN; PATHOLOGY; POLICY; PRACTICE GUIDELINE; PROTECTIVE EQUIPMENT; PUBLIC HEALTH; REGISTRATION; REVIEW; SCREENING; STORAGE; VIRUS INACTIVATION; VIRUS VIRULENCE; WORK ENVIRONMENT; WORKFLOW;

EBOLA VIRUS;

EID: 84871876858     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v4123932     Document Type: Review

References (18)

1. CDC. Biosafety in Microbiological and Biomedical Laboratories; U. S. Department of Health and Human Services: Washington, DC, USA, 2009.
2. NIAID. NIAID Biodefense Research Agenda for CDC Category A Agents; In Services, United States Department of Health and Human Services, National Institutes of Health: Bethesda, MD, USA, 2002.
3. Pastel, R.H.; Demmin, G.; Severson, G.; Torres-Cruz, R.; Trevino, J.; Kelly, J.; Arrison, J.; Christman, J. Clinical laboratories, the select agent program, and biological surety (biosurety). Clin. Lab. Med. 2006, 26, 299-312.
4. Carr, K.; Henchal, E.A.; Wilhelmsen, C.; Carr, B. Implementation of biosurety systems in a Department of Defense medical research laboratory. Biosecur. Bioterror. 2004, 2, 7-16.
5. National Select Agent Registry. Available online: http://www.selectagents.gov (accessed on 12 December 2012).
6. Kuhn, J.H. Filoviruses: A Compendium of 40 Years of Epidemiological, Clinical, and Laboratory Studies; Spring: Vienna, Austria, 2008; p. 411.
7. Snoy, P.J. Establishing efficacy of human products using animals: The US food and drug administration's "animal rule". Vet. Pathol. 2010, 47, 774-778.
8. US Depart of Health and Human Services, F.D.A. Draft Guidance for Industry-Essential Elements for Address Efficacy under the Animal Rule; F.D.A.: Silver Spring, MD, USA, 2009; Volume 74, pp. 3610-3611.
9. Skvorc, C.; Wilson, D.E. Developing a behavioral health screening program for BSL-4 laboratory workers at the National Institutes of Health. Biosecur. Bioterror. 2011, 9, 23-29.
10. Le Duc, J.W.; Anderson, K.; Bloom, M.E.; Estep, J.E.; Feldmann, H.; Geisbert, J.B.; Geisbert, T.W.; Hensley, L.; Holbrook, M.; Jahrling, P.B.; et al. Framework for leadership and training of Biosafety Level 4 laboratory workers. Emerg. Infect. Dis. 2008, 14, 1685-1688.
11. Blow, J.A.; Dohm, D.J.; Negley, D.L.; Mores, C.N. Virus inactivation by nucleic acid extraction reagents. J. Virol. Meth. 2004, 119, 195-198.
12. Towner, J.S.; Sealy, T.K.; Ksiazek, T.G.; Nichol, S.T. High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. J. Infect. Dis. 2007, 196, S205-S212.
13. Elliott, L.H.; McCormick, J.B.; Johnson, K.M. Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. J. Clin. Microbiol. 1982, 16, 704-708.
14. Mahanty, S.; Kalwar, R.; Rollin, P.E. Cytokine measurement in biological samples after physicochemical treatment for inactivation of biosafety level 4 viral agents. J. Med. Virol. 1999, 59, 341-345.
15. McKinney, M.D.; Moon, S.J.; Kulesh, D.A.; Larsen, T.; Schoepp, R.J. Detection of viral RNA from paraffin-embedded tissues after prolonged formalin fixation. J. Clin. Virol. 2009, 44, 39-42.
16. Nicholls, J.M.; Wong, L.P.; Chan, R.W.; Poon, L.L.; So, L.K.; Yen, H.L.; Fung, K.; van Poucke, S.; Peiris, J.S. Detection of highly pathogenic influenza and pandemic influenza virus in formalin fixed tissues by immunohistochemical methods. J. Virol. Meth. 2012, 179, 409-413.
17. Bente, D.A.; Friesen, J.; White, K.; Koll, J.; Kobinger, G.P. A computerized data-capture system for animal biosafety level 4 laboratories. JAALAS 2011, 50, 660-664.
18. Kortepeter, M.G.; Martin, J.W.; Rusnak, J.M.; Cieslak, T.J.; Warfield, K.L.; Anderson, E.L.; Ranadive, M.V. Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit. Emerg. Infect. Dis. 2008, 14, 881-887.